Hyperfine (HYPR) Stock Forecast & Price Target

Hyperfine is attractive fundamentally because its Model 2 Swoop platform is gaining traction across hospital, neurology office, and international channels, with more than 200 systems deployed worldwide and 12 units sold in 2Q26, up from 8 in 2Q25. The company benefits from a compelling ROI proposition, minimal pricing pushback, and recurring software, service, and support revenue, while gross margin stayed above 50% for four consecutive quarters and reached 50.7% in 2Q26. With $43.5M in cash, runway into 2028, and catalysts like AI software updates plus the contrast label expansion on track for 1H27, the company appears positioned for durable growth and improving operating leverage.

Hyperfine is viewed negatively because its revenue depends on early-stage Swoop adoption, and a slower-than-expected ramp could leave its still-small install base with lumpy quarterly performance and uneven sales. It also faces meaningful execution risk from international expansion, supplier concentration, and pricing pressure, including reliance on Benchmark Electronics and a single-source magnet supplier that could raise costs or disrupt demand if alternatives are unavailable. Beyond operations, the company’s capital-intensive model, competitive market, and regulatory exposure increase the risk of dilution, higher financing stress, and delays that could undermine profitability and growth.